Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilastatin does not alter superoxide dismutase activity.

R A Proctor, J A Textor

    Antimicrobial Agents and Chemotherapy
    |November 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges.

    European cells & materials·2015
    Same author

    Where does a Staphylococcus aureus vaccine stand?

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014
    Same author

    Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.

    Antimicrobial agents and chemotherapy·2012
    Same author

    Caecal intussusceptions in horses: a New Zealand perspective.

    Australian veterinary journal·2010
    Same author

    Renal agenesis in an alpaca cria.

    Australian veterinary journal·2007
    Same author

    Bacterial energetics and antimicrobial resistance.

    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2006

    Cilastatin inhibits dehydropeptidase-I but does not affect superoxide dismutase activity, even at high concentrations. This finding is important for understanding the drug's potential side effects and interactions.

    Area of Science:

    • Biochemistry
    • Enzymology
    • Pharmacology

    Background:

    • Dehydropeptidase-I is a zinc metalloenzyme that metabolizes the antibiotic imipenem.
    • Zinc is essential for the stability of mammalian superoxide dismutase.
    • Cilastatin is known to inhibit dehydropeptidase-I.

    Purpose of the Study:

    • To investigate whether cilastatin inhibits mammalian superoxide dismutase.
    • To determine the potential impact of cilastatin on cellular oxidative stress defense mechanisms.

    Main Methods:

    • Enzyme inhibition assays were performed.
    • Cilastatin was tested at concentrations threefold higher than typically found in urine.
    • Superoxide dismutase activity was measured in the presence of cilastatin.

    Related Experiment Videos

    Main Results:

    • Cilastatin effectively inhibited dehydropeptidase-I as expected.
    • Cilastatin did not inhibit superoxide dismutase activity at tested concentrations.
    • No significant impact on superoxide dismutase was observed.

    Conclusions:

    • Cilastatin's inhibitory effect is specific to dehydropeptidase-I.
    • Cilastatin does not interfere with the protective function of superoxide dismutase.
    • This suggests cilastatin is unlikely to disrupt oxidative stress balance through superoxide dismutase inhibition.